Human Pancreatic Cancer Cells Induce a MyD88-Dependent Stromal Response to Promote a Tumor-Tolerant Immune Microenvironment.
暂无分享,去创建一个
L. Moldawer | S. Wallet | C. Mathews | T. George | Kien Pham | S. Hughes | J. Trevino | K. Behrns | Brittney N. Newby | T. Brusko | Ryan M. Thomas | Chen Liu | Song Han | M. Gerber | Daniel Delitto | Andrea E. Delitto | Bayli Divita | Emily R Hartlage | D. Delitto
[1] S. Wallet,et al. Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture. , 2016, The American journal of pathology.
[2] Y. Thanavala,et al. High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy , 2016, Cancer Immunology, Immunotherapy.
[3] G. Sarosi,et al. The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival , 2015, BMC Cancer.
[4] E. Jaffee,et al. TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner , 2015, Oncotarget.
[5] L. Moldawer,et al. Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer , 2015, Cancer Immunology, Immunotherapy.
[6] M. Karin,et al. Immunity, inflammation, and cancer: an eternal fight between good and evil. , 2015, The Journal of clinical investigation.
[7] G. Sarosi,et al. Primary outgrowth cultures are a reliable source of human pancreatic stellate cells , 2015, Laboratory Investigation.
[8] Y. Kanai,et al. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer , 2015, British Journal of Cancer.
[9] G. Sarosi,et al. Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements. , 2015, The American journal of pathology.
[10] E. Furth,et al. Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma , 2015, Cancer Immunology Research.
[11] K. Matsushima,et al. Robust Antitumor Effects of Combined Anti–CD4-Depleting Antibody and Anti–PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice , 2015, Cancer Immunology Research.
[12] A. Amedei,et al. Pancreatic cancer: Role of the immune system in cancer progression and vaccine-based immunotherapy , 2014, Human vaccines & immunotherapeutics.
[13] G. Wahl,et al. Vitamin D Receptor-Mediated Stromal Reprogramming Suppresses Pancreatitis and Enhances Pancreatic Cancer Therapy , 2014, Cell.
[14] I. Pinchuk,et al. TLR4 Activation Enhances the PD-L1–Mediated Tolerogenic Capacity of Colonic CD90+ Stromal Cells , 2014, The Journal of Immunology.
[15] R. Hruban,et al. Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation , 2014, Cancer Immunology Research.
[16] Umar Mahmood,et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. , 2014, Cancer cell.
[17] Stephen A. Sastra,et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. , 2014, Cancer cell.
[18] A. Maitra,et al. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. , 2014, Gastroenterology.
[19] Benjamin D. Smith,et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.
[20] A. Maitra,et al. Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. , 2014, Cancer cell.
[21] Z. Trajanoski,et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.
[22] D. Lobo,et al. The presence of tumour-associated lymphocytes confers a good prognosis in pancreatic ductal adenocarcinoma: an immunohistochemical study of tissue microarrays , 2013, BMC Cancer.
[23] S. Martin,et al. Danger signalling during cancer cell death: origins, plasticity and regulation , 2013, Cell Death and Differentiation.
[24] Jonathan B. Mitchem,et al. Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis , 2013, Clinical Cancer Research.
[25] J. Furuse,et al. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer , 2013, British Journal of Cancer.
[26] G. Trinchieri,et al. Molecular Pathways Molecular Pathways : Toll-like Receptors in the Tumor Microenvironment — Poor Prognosis or New Therapeutic Opportunity , 2013 .
[27] Alexander A. Fingerle,et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications , 2012, Nature Reviews Gastroenterology &Hepatology.
[28] Yan Liu,et al. An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. , 2012, The Journal of clinical investigation.
[29] Wei Hu,et al. Priming microenvironments dictate cytokine requirements for T helper 17 cell lineage commitment. , 2011, Immunity.
[30] D. Baltimore,et al. Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells , 2011, Proceedings of the National Academy of Sciences.
[31] H. Friess,et al. StellaTUM: current consensus and discussion on pancreatic stellate cell research , 2011, Gut.
[32] M. Braga,et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer , 2011, The Journal of experimental medicine.
[33] S. Rosenberg,et al. Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.
[34] Yuan Tian,et al. Expression and significance of TLR4 and HIF-1alpha in pancreatic ductal adenocarcinoma. , 2010, World journal of gastroenterology.
[35] C. Erridge. Endogenous ligands of TLR2 and TLR4: agonists or assistants? , 2010, Journal of leukocyte biology.
[36] Maria T. Abreu,et al. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function , 2010, Nature Reviews Immunology.
[37] Yusuke Sato,et al. Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment , 2009, Cancer Microenvironment.
[38] S. Youssef,et al. Differential Regulation of Chemokines by IL-17 in Colonic Epithelial Cells1 , 2008, The Journal of Immunology.
[39] Helmut Friess,et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[40] D. Tuveson,et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. , 2007, Cancer research.
[41] Weiping Zou,et al. Immunosuppressive networks in the tumour environment and their therapeutic relevance , 2005, Nature Reviews Cancer.
[42] H. Moses,et al. Stromal fibroblasts in cancer initiation and progression , 2004, Nature.
[43] Dirk E. Smith,et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction , 2001, Nature.
[44] V. Engelhard,et al. Perforin-dependent cytotoxic activity and lymphokine secretion by CD4+ T cells are regulated by CD8+ T cells. , 1997, Journal of immunology.
[45] Jian Ye,et al. The role and regulation of human Th17 cells in tumor immunity. , 2013, The American journal of pathology.
[46] Holden T. Maecker,et al. Erratum: Standardizing immunophenotyping for the Human Immunology Project , 2012, Nature Reviews Immunology.
[47] M. Willson,et al. CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011 .
[48] Deborah M. Brown,et al. IL-2 and antigen dose differentially regulate perforin- and FasL-mediated cytolytic activity in antigen specific CD4+ T cells. , 2009, Cellular immunology.
[49] F. Marincola,et al. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.